(Q37799845)

23 August 2017

title

PLX4032: does it keep its promise for metastatic melanoma treatment? (English)

1 reference

23 August 2017

1 reference

4

Dirk Schadendorf

1 reference

23 August 2017

author name string

Elisabeth Livingstone

series ordinal

1

1 reference

23 August 2017

Lisa Zimmer

series ordinal

2

1 reference

23 August 2017

Sarah Piel

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

14 October 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

19

1 reference

23 August 2017

issue

11

1 reference

23 August 2017

page(s)

1439-1449

1 reference

Increasing burden of melanoma in the United States

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Management of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

UK guidelines for the management of cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Cell signaling and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Selective Raf inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Drug discovery: inhibitors that activate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.527945

10.1517/13543784.2010.527945

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference